Affluent Medical SA

Paris Stock Exchange AFME.PA

Affluent Medical SA Shareholders' Equity for the year ending December 31, 2023: USD 34.74 M

Affluent Medical SA Shareholders' Equity is USD 34.74 M for the year ending December 31, 2023, a -4.04% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Affluent Medical SA Shareholders' Equity for the year ending December 31, 2022 was USD 36.20 M, a -26.96% change year over year.
Affluent Medical SA Shareholders' Equity for the year ending December 31, 2021 was USD 49.56 M, a 14.96% change year over year.
Affluent Medical SA Shareholders' Equity for the year ending December 31, 2020 was USD 43.11 M, a 24.06% change year over year.
Affluent Medical SA Shareholders' Equity for the year ending December 31, 2019 was USD 34.75 M, a -52.85% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

Paris Stock Exchange: AFME.PA

Affluent Medical SA

CEO	Sebastien Ladet Ph.D.
IPO Date	June 14, 2021
Location	France
Headquarters	320, avenue Archimède
Employees	66
Sector	Technology
Industries 3D Printing Biotechnology Clinical Trials Composite Materials Medical Instruments Robotics

Description

Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.

Key trends

Past 5 years